Innovative retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable interest within the medical community. Initial clinical trials have revealed impressive decreases in overall mass and gains in metabolic markers for patients with excess weight . Researchers believe this unique approach could si